# Lexaria Bioscience (NASDAQ: LEXX) Releases Q3 2024 Results; Offers Roadmap for GLP-1 Study

* The company provided updates for its study programs for 2024, with a focus on its glucagon-like peptide-1 (“GLP-1”) agonist research program, targeting a significant step up in addressing worldwide diabetes and obesity, a tremendous market
* Lexaria has its Human Pilot Study #3 lined up, as well as its chronic dosing human study, both studies will begin dosing later this year

 Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released its fiscal report for the third quarter of the 2024 financial year (“Q3, 2024”). Of note was growth in cash and marketable securities from $1.5 million during the same period in the 2023 financial year to $8.5 million as of May 31, 2024. The company reduced certain R&D expenditures and experienced other savings (https://cnw.fm/OxPux).

 Most importantly, however, were the program updates for initiatives it embarked on for 2024. A highlight of its projects has been its glucagon-like peptide-1 (“GLP-1”) agonist research program. GLP-1, a class of drugs, has demonstrated an ability to significantly address diabetes and obesity. What Lexaria’s unique…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

 About CBDWire

 CBDWire (“CBDW”) is a specialized communications platform with a focus on CBD related news and updates in the cannabidiol (“CBD”) sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled recognition and brand awareness.

 CBDW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from CBDWire, text “CBDWire” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.CBDWire.com

 Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer

 CBDWireDenver, COwww.CBDWire.com303.498.7722 OfficeEditor@CBDWire.com

 CBDWire is powered by IBN 

[Original/Source Press Release](https://rss.investorbrandnetwork.com/ibn-prem/lexaria-bioscience-nasdaq-lexx-releases-q3-2024-results-offers-roadmap-for-glp-1-study/)
                    

[Newsramp.com TLDR](None) 

https://www.reddit.com/r/HealthCareNewsInfo/comments/1f2gg4i/lexaria_bioscience_nasdaq_lexx_releases_q3_2024/